Skip to main content
Premium Trial:

Request an Annual Quote

Berry Genomics, Prenetics to Form Chinese Consumer Genomics JV

NEW YORK (GenomeWeb) — Berry Genomics has partnered with Hong Kong-based Prenetics to offer a range of direct-to-consumer genetic testing services to the Chinese market, the companies announced today.

Under the terms of their deal, Beijing-based Berry and Prenetics will create a joint venture to sell integrated digital health and genetics testing services directly to consumers in mainland China. The products will be available for order online, beginning in the first quarter of 2019, the companies said.

Berry and Prenetics added that the joint venture will seek to collaborate with insurers, governments, and other key stakeholders in order to meet local market needs. Additional terms were not disclosed.

"Berry is an industry leader in [non-invasive prenatal testing] and has developed a proven business model in genomics around a complex challenge in mainland China," Prenetics Cofounder and CEO Danny Yeung said in a statement. "Together with Berry, we will create awareness on health and the power of prevention through genetic understanding."

In January, Berry partnered with 10x Genomics to offer a new sequencing-based technology for NIPT in China. A few months later, Prenetics acquired UK-based wellness genetics company DNAFit for $10 million, marking its first step into the consumer genomics space.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more